Overview

24-hour IOP-lowering Effect of Brimonidine 0.1%

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension
Phase:
Phase 4
Details
Lead Sponsor:
Allergan
Treatments:
Brimonidine Tartrate